The podcaster-to-policy pathway poses risks to patients, innovation

Wellness influencers, telehealth companies and MAHA enthusiasts are rejoicing over the Trump administration’s moves to reduce barriers to selling peptides and accessing ibogaine. Everyone else should be alarmed.

It is easy to become numb to disconcerting news coming out of FDA. There’s been a constant stream, from mass firings and leadership churn to anti-vaccine policies and regulatory reversals that delayed or derailed therapies for devastating diseases. The picture isn’t uniformly dark. Good drugs are being approved, and positive policies, from pathways for drugs to treat ultrarare conditions to streamlining biosimilars development, have been announced and steps taken to implement them. ...